{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:58:02Z","timestamp":1747184282914,"version":"3.40.5"},"reference-count":127,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>In December 2019, the severe acute respiratory syndrome virus\u20102 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off\u2010label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely.<\/jats:p>","DOI":"10.1111\/cts.12866","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T21:53:12Z","timestamp":1600293192000},"page":"1023-1033","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Important Pharmacogenetic Information for Drugs Prescribed During the SARS\u2010CoV\u20102 Infection (COVID\u201019)"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando Universidad Aut\u00f3noma de Madrid (UAM) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Plataforma SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-0466","authenticated-orcid":false,"given":"Dora","family":"Koller","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando Universidad Aut\u00f3noma de Madrid (UAM) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-3135","authenticated-orcid":false,"given":"Miriam","family":"Saiz\u2010Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando Universidad Aut\u00f3noma de Madrid (UAM) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"},{"name":"Research Unit Fundaci\u00f3n Burgos por la Investigaci\u00f3n de la Salud Hospital Universitario de Burgos Burgos Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-6845","authenticated-orcid":false,"given":"Marcos","family":"Navares\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando Universidad Aut\u00f3noma de Madrid (UAM) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad\u2010Santos","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department Hospital Universitario de La Princesa Instituto Te\u00f3filo Hernando Universidad Aut\u00f3noma de Madrid (UAM) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"},{"name":"UICEC Hospital Universitario de La Princesa Plataforma SCReN (Spanish Clinical Research Network) Instituto de Investigaci\u00f3n Sanitaria La Princesa (IP) Madrid Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"e_1_2_21_1_1","unstructured":"World Health Organization.Coronavirus disease (COVID\u201019) Situation Report \u2013 124.<https:\/\/www.who.int\/docs\/default\u2010source\/coronaviruse\/situation\u2010reports\/20200523\u2010covid\u201019\u2010sitrep\u2010124.pdf?sfvrsn=9626d639_2>."},{"key":"e_1_2_21_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117765"},{"journal-title":"JAMA","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID\u201019): a review","author":"Sanders J.M.","key":"e_1_2_21_3_1"},{"key":"e_1_2_21_4_1","unstructured":"World Health Organization.Off\u2010label use of medicines for COVID\u201019.<https:\/\/www.who.int\/news\u2010room\/commentaries\/detail\/off\u2010label\u2010use\u2010of\u2010medicines\u2010for\u2010covid\u201019>."},{"journal-title":"Br. J. Clin. Pharmacol","article-title":"COVID\u201019 treatment in patients with comorbidities: Awareness of drug\u2010drug interactions","author":"Back D.","key":"e_1_2_21_5_1"},{"key":"e_1_2_21_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.011"},{"journal-title":"Eur. J. Haematol.","article-title":"COVID\u201019 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose\u20106\u2010phosphate dehydrogenase deficiency","author":"Beauverd Y.","key":"e_1_2_21_7_1"},{"key":"e_1_2_21_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23296"},{"key":"e_1_2_21_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/346853"},{"key":"e_1_2_21_10_1","unstructured":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios (AEMPS).Tratamientos disponibles sujetos a condiciones especiales de acceso para el manejo de la infecci\u00f3n respiratoria por SARS\u2010CoV\u20102.<https:\/\/www.aemps.gob.es\/la\u2010aemps\/ultima\u2010informacion\u2010de\u2010la\u2010aemps\u2010acerca\u2010del\u2010covid%E2%80%9119\/tratamientos\u2010disponibles\u2010para\u2010el\u2010manejo\u2010de\u2010la\u2010infeccion\u2010respiratoria\u2010por\u2010sars\u2010cov\u20102\/>."},{"key":"e_1_2_21_11_1","unstructured":"COVID\u201019 Treatment Guidelines Panel.Coronavirus Disease 2019 (COVID\u201019) Treatment Guidelines. National Institutes of Health <https:\/\/www.covid19treatmentguidelines.nih.gov\/>."},{"journal-title":"Ann. Intern. Med.","article-title":"Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID\u201019: a living systematic review","author":"Hernandez A.V.","key":"e_1_2_21_12_1"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa130"},{"journal-title":"Lancet","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID\u201019: a multinational registry analysis","author":"Mehra M.R.","key":"e_1_2_21_14_1"},{"key":"e_1_2_21_15_1","unstructured":"US Food and Drug Administration (FDA) News Release.Coronavirus (COVID\u201019) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. June 15 2020. <https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010revokes\u2010emergency\u2010use\u2010authorization\u2010chloroquine\u2010and>. Last accessed July 9 2020."},{"key":"e_1_2_21_16_1","unstructured":"COVID\u201019 Treatment Guidelines Panel.Coronavirus Disease 2019 (COVID\u201019) Treatment Guidelines. National Institutes of Health.<https:\/\/www.covid19treatmentguidelines.nih.gov\/>. Last accessed July 9 2020."},{"key":"e_1_2_21_17_1","unstructured":"World Health Organization.Q&A: Hydroxychloroquine and COVID\u201019.<https:\/\/www.who.int\/news\u2010room\/q\u2010a\u2010detail\/q\u2010a\u2010hydroxychloroquine\u2010and\u2010covid\u201019>."},{"key":"e_1_2_21_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"e_1_2_21_19_1","unstructured":"Plaquenil\u00aehydroxychloroquine drug label.<https:\/\/amiko.oddb.org\/de\/fi?gtin=53831>. German (2019)."},{"key":"e_1_2_21_20_1","unstructured":"ARALEN\u00aeChloroquine phosphate drug label.<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/006002s044lbl.pdf> (2017)."},{"key":"e_1_2_21_21_1","unstructured":"Nivaquine\u00aedrug label for chloroquine.<https:\/\/amiko.oddb.org\/de\/fi?gtin=18889&highlight>. German. (2019)."},{"key":"e_1_2_21_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12469"},{"key":"e_1_2_21_23_1","unstructured":"Centers for Disease Control and Prevention (CDC).Treatment of Malaria: Guidelines for Clinicians (United States). <https:\/\/www.cdc.gov\/malaria\/diagnosis_treatment\/clinicians1.html>."},{"key":"e_1_2_21_24_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15085"},{"key":"e_1_2_21_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.748"},{"key":"e_1_2_21_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0131"},{"key":"e_1_2_21_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00489"},{"key":"e_1_2_21_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"e_1_2_21_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"e_1_2_21_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"e_1_2_21_31_1","unstructured":"European Medicines Agency.Veklury\u00ae remdesivir.<https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veklury#overview\u2010section>."},{"key":"e_1_2_21_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2020.100128"},{"key":"e_1_2_21_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa105"},{"key":"e_1_2_21_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31030-8"},{"key":"e_1_2_21_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801364-9.00025-0"},{"key":"e_1_2_21_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.091"},{"key":"e_1_2_21_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.312156"},{"key":"e_1_2_21_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000237862.94083.45"},{"key":"e_1_2_21_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-020-04920-4"},{"journal-title":"J. Med. Virol.","article-title":"ACE2 and prognosis of COVID\u201019. Insights from Bartter\u2019s and Gitelman\u2019s syndromes patients","author":"Cal\u00f2 L.A.","key":"e_1_2_21_40_1"},{"key":"e_1_2_21_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002450"},{"key":"e_1_2_21_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0707-7"},{"key":"e_1_2_21_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200204000-00010"},{"key":"e_1_2_21_44_1","first-page":"2460","article-title":"Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients","volume":"20","author":"G\u00f6kta\u015f M.T.","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"journal-title":"Pharmacogenomics","article-title":"How to make P\u2010glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures?","author":"Zubiaur P.","key":"e_1_2_21_45_1"},{"key":"e_1_2_21_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13031"},{"key":"e_1_2_21_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7057.591"},{"key":"e_1_2_21_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000025845"},{"key":"e_1_2_21_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199812000-00017"},{"key":"e_1_2_21_50_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110018"},{"journal-title":"J. Microbiol. Immunol. Infect.","article-title":"ACE2 receptor polymorphism: Susceptibility to SARS\u2010CoV\u20102, hypertension, multi\u2010organ failure, and COVID\u201019 disease outcome","author":"Devaux C.A.","key":"e_1_2_21_51_1"},{"key":"e_1_2_21_52_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i2.123"},{"key":"e_1_2_21_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25798"},{"key":"e_1_2_21_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.203"},{"key":"e_1_2_21_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.34"},{"key":"e_1_2_21_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04904-7"},{"key":"e_1_2_21_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03055.x"},{"key":"e_1_2_21_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.015"},{"key":"e_1_2_21_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31101-6"},{"key":"e_1_2_21_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa224"},{"key":"e_1_2_21_61_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210132"},{"key":"e_1_2_21_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3285"},{"key":"e_1_2_21_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgg.2020.02.001"},{"key":"e_1_2_21_64_1","unstructured":"KALETRA\u00aelopinavir and ritonavir drug label.<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021251s052_021906s046lbl.pdf> (2000)."},{"key":"e_1_2_21_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2014.67"},{"key":"e_1_2_21_66_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2016.1170808"},{"key":"e_1_2_21_67_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.104391"},{"key":"e_1_2_21_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.6.1104"},{"key":"e_1_2_21_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.690"},{"key":"e_1_2_21_70_1","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.10.89"},{"journal-title":"Microbiology","article-title":"Atazanavir inhibits SARS\u2010CoV\u20102 replication and pro\u2010inflammatory cytokine production","author":"Fintelman\u2010Rodrigues N.","key":"e_1_2_21_71_1"},{"key":"e_1_2_21_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.03.025"},{"key":"e_1_2_21_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.269"},{"key":"e_1_2_21_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x"},{"key":"e_1_2_21_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30749-2"},{"key":"e_1_2_21_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3282f82297"},{"key":"e_1_2_21_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3481-8"},{"key":"e_1_2_21_78_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120113"},{"key":"e_1_2_21_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200311000-00003"},{"key":"e_1_2_21_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01075-5"},{"key":"e_1_2_21_81_1","unstructured":"World Health Organization (WHO).Updated: WHO Now Doesn\u2019t Recommend Avoiding Ibuprofen For COVID\u201019 Symptoms. <https:\/\/www.sciencealert.com\/who\u2010recommends\u2010to\u2010avoid\u2010taking\u2010ibuprofen\u2010for\u2010covid\u201019\u2010symptoms?__twitter_impression=true>."},{"key":"e_1_2_21_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2020.000021"},{"journal-title":"Clin. Pharmacol. Ther.","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti\u2010inflammatory drugs","author":"Theken K.N.","key":"e_1_2_21_83_1"},{"key":"e_1_2_21_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"e_1_2_21_85_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969050-00007"},{"key":"e_1_2_21_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17752037"},{"key":"e_1_2_21_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716653745"},{"journal-title":"Pharmacogenet. Genomics","article-title":"Interleukin\u20106\u2010receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis","author":"Enevold C.","key":"e_1_2_21_88_1"},{"key":"e_1_2_21_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.88"},{"key":"e_1_2_21_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.06.016"},{"key":"e_1_2_21_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1341"},{"key":"e_1_2_21_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0462-8"},{"key":"e_1_2_21_93_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20048561"},{"key":"e_1_2_21_94_1","unstructured":"SYLVANT\u00ae siltuximab drug label.<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125496s000lbl.pdf>."},{"key":"e_1_2_21_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00211-2"},{"key":"e_1_2_21_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199512000-00019"},{"key":"e_1_2_21_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0153-3"},{"key":"e_1_2_21_98_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.012161"},{"key":"e_1_2_21_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00745.x"},{"key":"e_1_2_21_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.113"},{"key":"e_1_2_21_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2020.04.012"},{"key":"e_1_2_21_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41021-016-0066-4"},{"key":"e_1_2_21_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-2786"},{"key":"e_1_2_21_104_1","first-page":"5284","article-title":"Smoking and lung cancer: scientific challenges and opportunities","volume":"54","author":"Wynder E.L.","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_21_105_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01733.x"},{"key":"e_1_2_21_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x"},{"key":"e_1_2_21_107_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060040-00006"},{"key":"e_1_2_21_108_1","unstructured":"A double\u2010blind placebo\u2010controlled clinical trial of fluvoxamine for symptomatic individuals with COVID\u201019 infection (STOP COVID).<https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04342663> (2020)."},{"key":"e_1_2_21_109_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5266"},{"key":"e_1_2_21_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8"},{"key":"e_1_2_21_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_2_21_112_1","unstructured":"Luvox\u00aefluvoxamine maleate drug label.<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022235lbl.pdf> (1994)."},{"key":"e_1_2_21_113_1","unstructured":"Floxyfral\u00aelabel for fluvoxamine.<https:\/\/amiko.oddb.org\/de\/fi?gtin=44603>."},{"key":"e_1_2_21_114_1","unstructured":"Dutch Pharmacogenetics Working Group Guidelines.November 2018. <https:\/\/www.knmp.nl\/downloads\/pharmacogenetic\u2010recommendations\u2010november\u20102018.pdf> (2018)."},{"journal-title":"J. Allergy Clin. Immunol","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID\u201019): a multicenter, single\u2010blind, randomized controlled trial","author":"Cao Y.","key":"e_1_2_21_115_1"},{"key":"e_1_2_21_116_1","unstructured":"Jakavi ruxolitinib drug label.<https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jakavi> (2011)."},{"key":"e_1_2_21_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"e_1_2_21_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"e_1_2_21_119_1","unstructured":"OLUMIANT\u00aebaricitinib drug label.<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf> (2018)."},{"key":"e_1_2_21_120_1","unstructured":"European Medicines Agency Kineret\u00ae anakinra drug label.<https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/kineret\u2010epar\u2010product\u2010information_es.pdf>."},{"key":"e_1_2_21_121_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488412803305821"},{"journal-title":"Reumatol. Cl\u00ednica","article-title":"Propuesta de uso de anakinra en el distr\u00e9s respiratorio agudo secundario a COVID\u201019","author":"Mu\u00f1oz\u2010Jim\u00e9nez A.","key":"e_1_2_21_122_1"},{"key":"e_1_2_21_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364228"},{"key":"e_1_2_21_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.013"},{"key":"e_1_2_21_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-020-00216-7"},{"key":"e_1_2_21_126_1","doi-asserted-by":"publisher","DOI":"10.4238\/2013.January.24.2"},{"key":"e_1_2_21_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0255-8"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12866","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12866","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:31:25Z","timestamp":1693819885000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/cts.12866"],"URL":"https:\/\/doi.org\/10.1111\/cts.12866","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"type":"print","value":"1752-8054"},{"type":"electronic","value":"1752-8062"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"2020-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}